Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.

ABSTRACT:

Objective

Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. It has a wide range of clinical applications in various cancers and retinal diseases. The drugs entered the Chinese market by a large margin in 2017, and the user population changed to some extent. This study reevaluated the safety of bevacizumab through an analysis of the World Pharmacovigilance database (Food and Drug Administration Open Vigil 2.1) in conjunction with a comprehensive meta-analysis of RCTs.

Methods

Real-world pharmacovigilance data originating from case reports were mined using Open Vigil and coded at the preferred term (PT) level using the Standardized MedDRA Query. Proportional reporting ratios (PRR) and reporting odds ratios (ROR) were used to detect safety signals

SUBMITTER: Wang L 

PROVIDER: S-EPMC10763108 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature